Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
289.9 USD | +7.50% | -2.88% | -8.16% |
May. 21 | Genmab A/S Reaffirms Financial Guidance for 2024 | CI |
May. 21 | Genmab A/S completed the acquisition of ProfoundBio, Inc. | CI |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
- From a short-term investment perspective, the company presents a deteriorated fundamental situation
Strengths
- According to sales estimates from analysts polled by Standard & Poor's, the company is among the best with regard to growth.
- Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
- Margins returned by the company are among the highest on the stock exchange list. Its core activity clears big profits.
- Thanks to a sound financial situation, the firm has significant leeway for investment.
- Over the past year, analysts have regularly revised upwards their sales forecast for the company.
- Sales forecast by analysts have been recently revised upwards.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
- Analyst opinion has improved significantly over the past four months.
- Consensus analysts have strongly revised their opinion of the company over the past 12 months.
- Historically, the company has been releasing figures that are above expectations.
Weaknesses
- The company benefits from high valuations in earnings multiples.
- With an enterprise value anticipated at 4.99 times the sales for the current fiscal year, the company turns out to be overvalued.
- The company appears highly valued given the size of its balance sheet.
- The valuation of the company is particularly high given the cash flows generated by its activity.
- For the past year, analysts have significantly revised downwards their profit estimates.
- For the last twelve months, the analysts covering the company have given a bearish overview of EPS estimates, resulting in frequent downward revisions.
- Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
Ratings chart - Surperformance
Sector: Biotechnology & Medical Research
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-8.16% | 18.18B | - | ||
+9.83% | 115B | B+ | ||
+10.80% | 105B | B+ | ||
-10.84% | 22.71B | B+ | ||
-1.40% | 21.83B | B | ||
-41.92% | 16.52B | A- | ||
-15.11% | 16.01B | B | ||
+6.62% | 14.14B | C+ | ||
+17.53% | 10.71B | C+ | ||
-30.73% | 7.6B | D |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- GMAB Stock
- GNMSF Stock
- Ratings Genmab A/S